NASDAQ:HZNP - Horizon Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $21.20 -0.04 (-0.19 %) (As of 02/22/2019 04:00 PM ET)Previous Close$21.24Today's Range$20.86 - $21.5452-Week Range$12.55 - $24.03Volume2.07 million shsAverage Volume1.40 million shsMarket Capitalization$3.55 billionP/E Ratio17.97Dividend YieldN/ABeta1.15 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease; and HemoShear Therapeutics, LLC to discover and develop therapeutics for gout. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. Receive HZNP News and Ratings via Email Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP Previous Symbol CUSIP44047T10 CIK1492426 Webwww.horizonpharma.com Phone011-353-1772-2100Debt Debt-to-Equity Ratio2.06 Current Ratio1.94 Quick Ratio1.86Price-To-Earnings Trailing P/E Ratio17.97 Forward P/E Ratio16.31 P/E Growth1.07 Sales & Book Value Annual Sales$1.06 billion Price / Sales3.36 Cash Flow$3.0028 per share Price / Cash Flow7.06 Book Value$6.05 per share Price / Book3.50Profitability EPS (Most Recent Fiscal Year)$1.18 Net Income$-410,520,000.00 Net Margins-18.70% Return on Equity27.14% Return on Assets6.09%Miscellaneous Employees1,010 Outstanding Shares167,626,000Market Cap$3.55 billion Next Earnings Date2/27/2019 (Confirmed) OptionableOptionable Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions What is Horizon Pharma's stock symbol? Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP." How will Horizon Pharma's stock buyback program work? Horizon Pharma declared that its Board of Directors has authorized a share buyback program on Sunday, June 4th 2017, which permits the company to buyback 1,000% of outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's management believes its shares are undervalued. How were Horizon Pharma's earnings last quarter? Horizon Pharma PLC (NASDAQ:HZNP) issued its earnings results on Wednesday, August, 8th. The biopharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.17. The biopharmaceutical company had revenue of $302.84 million for the quarter, compared to the consensus estimate of $275.51 million. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The firm's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.41 earnings per share. View Horizon Pharma's Earnings History. When is Horizon Pharma's next earnings date? Horizon Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Horizon Pharma. How can I listen to Horizon Pharma's earnings call? Horizon Pharma will be holding an earnings conference call on Wednesday, February 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. What price target have analysts set for HZNP? 12 Wall Street analysts have issued 1 year price targets for Horizon Pharma's stock. Their predictions range from $18.00 to $35.00. On average, they anticipate Horizon Pharma's share price to reach $23.7273 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price. View Analyst Price Targets for Horizon Pharma. What is the consensus analysts' recommendation for Horizon Pharma? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Pharma in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Pharma. What are Wall Street analysts saying about Horizon Pharma stock? Here are some recent quotes from research analysts about Horizon Pharma stock: 1. According to Zacks Investment Research, "Horizon faces intense competition from pharmaceutical and biotechnology companies, and universities and other research institutions.Horizon is working on label expansion of drug like Ravicti. Failing to gain regulatory approval for label expansions would hamper drugs’ commercial potential. The company is exploring a broader clinical profile of Krystexxa including adapting its MIRROR immunomodulation study based on promising recent data to support the potential for registration.The company’s clinical programs continue to advance, with the recent presentation of new teprotumumab phase II data that underscore the durable efficacy observed in thyroid eye disease. Shares of the company have outperformed the industry in the past year. Estimates have remained stable ahead of the Q4 results. The company has positive earnings surprise in the last few quarters." (2/8/2019) 2. Mizuho analysts commented, "We believe the event could have +10% upside/-30% downside to the stock (and is risky), because expectations for a positive read-out are already quite high. HZNP already advanced +17% YTD into the event. The company has discussed with us the opportunity as capturing 50% share in the 15,000-20,000 moderate/ severe active TED patients, with a $100K net price for treatment to achieve its estimates of >$750M. In contrast, we currently assume a ~15% share, and net price of $210K/treatment in 2020, with net price increases of 5% thereafter (based on prior mgmt. commentary on Orphan pricing). We will update our estimates after the data, which we believe will determine the commercial attractiveness of this compound. We reiterate our Neutral rating, and continue to view 2019 consensus earnings estimates as too high." (2/7/2019) 3. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for HZNP shares to $23 from $21. The increase in our PT is driven by multiple expansion. We think this is deserved because continued solid execution from the management team underscores our belief that the peak sales potential of HZNP’s orphan/rare disease as well as rheumatology businesses are underappreciated." (10/18/2018) 4. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018) Has Horizon Pharma been receiving favorable news coverage? Media headlines about HZNP stock have trended positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Horizon Pharma earned a news impact score of 2.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Horizon Pharma's key competitors? Some companies that are related to Horizon Pharma include GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT) and Dr.Reddy's Laboratories (RDY). What other stocks do shareholders of Horizon Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Pharma investors own include Opko Health (OPK), Celgene (CELG), Alibaba Group (BABA), Gilead Sciences (GILD), Allergan (AGN), Netflix (NFLX), Bausch Health Companies (BHC), Micron Technology (MU), Inovio Pharmaceuticals (INO) and AbbVie (ABBV). Who are Horizon Pharma's key executives? Horizon Pharma's management team includes the folowing people: Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 49)Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 54) Who are Horizon Pharma's major shareholders? Horizon Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.29%), Dimensional Fund Advisors LP (3.07%), venBio Select Advisor LLC (2.60%), D. E. Shaw & Co. Inc. (2.01%), Eagle Asset Management Inc. (1.61%) and Northern Trust Corp (1.39%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Geoffrey M Curtis, Michael G Grey, Robert Carey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma. Which institutional investors are selling Horizon Pharma stock? HZNP stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Brandywine Global Investment Management LLC, Dimensional Fund Advisors LP, Segall Bryant & Hamill LLC, Barings LLC, Bank of Montreal Can, venBio Select Advisor LLC and Prudential Financial Inc.. Company insiders that have sold Horizon Pharma company stock in the last year include Brian K Beeler, Geoffrey M Curtis and Timothy P Walbert. View Insider Buying and Selling for Horizon Pharma. Which institutional investors are buying Horizon Pharma stock? HZNP stock was bought by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Jennison Associates LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Penserra Capital Management LLC and Oak Ridge Investments LLC. View Insider Buying and Selling for Horizon Pharma. How do I buy shares of Horizon Pharma? Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Horizon Pharma's stock price today? One share of HZNP stock can currently be purchased for approximately $21.20. How big of a company is Horizon Pharma? Horizon Pharma has a market capitalization of $3.55 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe. What is Horizon Pharma's official website? The official website for Horizon Pharma is http://www.horizonpharma.com. How can I contact Horizon Pharma? Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected] MarketBeat Community Rating for Horizon Pharma (NASDAQ HZNP)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 719 (Vote Outperform)Underperform Votes: 344 (Vote Underperform)Total Votes: 1,063MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?